Tolerx
closedNovel therapies that modulate T-cell activities to treat patients with autoimmune diseases, diabetes and cancer.
Launch date
Employees
Market cap
-
Enterprise valuation
€5—8m (Dealroom.co estimates Dec 2010.)
Cambridge Massachusetts (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$17.0m | Series B | ||
$35.0m | Series C | ||
$31.0m | Series D | ||
$61.0m | Series D | ||
N/A | $1.5m | Early VC | |
Total Funding | €132m |
Related Content
Recent News about Tolerx
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.